You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

CIPROFLOXACIN - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for ciprofloxacin and what is the scope of freedom to operate?

Ciprofloxacin is the generic ingredient in eighteen branded drugs marketed by Bayer Hlthcare, Chartwell, Alk Abello, Bayer Pharms, Baxter Hlthcare Corp, Bedford Labs, Dr Reddys, Fresenius Kabi Usa, Hikma Farmaceutica, Hospira, Baxter Hlthcare, Bedford, Inforlife, Teva Pharms, Sandoz, Altaire Pharms Inc, Amring Pharms, Fdc Ltd, Rising, Rubicon, Sciegen Pharms Inc, The J Molner, Watson Labs Inc, Key Therap, Depomed Inc, Aiping Pharm Inc, Amneal, Aurobindo Pharma, Barr, Carlsbad, Dr Reddys Labs Ltd, Hikma, Ivax Sub Teva Pharms, Natco, Nostrum Labs, Pliva, Sun Pharm Inds Ltd, Taro, Teva, Unique, Watson Labs, Yiling, Laboratorios Salvat, Ani Pharms, Endo Operations, Fosun Pharma, Sentiss, and Sun Pharm, and is included in sixty-six NDAs. There are ten patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Ciprofloxacin has one hundred and fifty patent family members in twenty countries.

There are thirty-four drug master file entries for ciprofloxacin. Five suppliers are listed for this compound. There are four tentative approvals for this compound.

Drug Prices for CIPROFLOXACIN

See drug prices for CIPROFLOXACIN

Drug Sales Revenue Trends for CIPROFLOXACIN

See drug sales revenues for CIPROFLOXACIN

Recent Clinical Trials for CIPROFLOXACIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Prostate Cancer FoundationPhase 1/Phase 2
Institute of Cancer Research, United KingdomPhase 1/Phase 2
Shanghai Pulmonary Hospital, Shanghai, ChinaPhase 4

See all CIPROFLOXACIN clinical trials

Generic filers with tentative approvals for CIPROFLOXACIN
Applicant Application No. Strength Dosage Form
⤷  Sign Up⤷  Sign UpEQ 750MG BASETABLET;ORAL
⤷  Sign Up⤷  Sign UpEQ 500MG BASETABLET;ORAL
⤷  Sign Up⤷  Sign UpEQ 250MG BASETABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for CIPROFLOXACIN
Medical Subject Heading (MeSH) Categories for CIPROFLOXACIN
Paragraph IV (Patent) Challenges for CIPROFLOXACIN
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
CIPRO Oral Suspension ciprofloxacin 250 mg/5 mL and 500 mg/ 5 mL 020780 1 2009-10-16

US Patents and Regulatory Information for CIPROFLOXACIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Dr Reddys Labs Ltd CIPROFLOXACIN EXTENDED RELEASE ciprofloxacin; ciprofloxacin hydrochloride TABLET, EXTENDED RELEASE;ORAL 077701-002 Oct 31, 2007 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Chartwell CIPROFLOXACIN HYDROCHLORIDE ciprofloxacin hydrochloride TABLET;ORAL 076896-003 Nov 4, 2004 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Rising CIPROFLOXACIN EXTENDED RELEASE ciprofloxacin; ciprofloxacin hydrochloride TABLET, EXTENDED RELEASE;ORAL 078183-001 Mar 22, 2007 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Bayer Hlthcare CIPRO ciprofloxacin INJECTABLE;INJECTION 019847-002 Dec 26, 1990 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Bayer Hlthcare CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER ciprofloxacin INJECTABLE;INJECTION 019857-001 Dec 26, 1990 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Baxter Hlthcare CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER ciprofloxacin INJECTABLE;INJECTION 077888-001 Mar 18, 2008 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Bedford CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER ciprofloxacin INJECTABLE;INJECTION 078114-001 Mar 18, 2008 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CIPROFLOXACIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bayer Hlthcare CIPRO ciprofloxacin FOR SUSPENSION;ORAL 020780-002 Sep 26, 1997 ⤷  Sign Up ⤷  Sign Up
Bayer Hlthcare CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER ciprofloxacin INJECTABLE;INJECTION 019857-001 Dec 26, 1990 ⤷  Sign Up ⤷  Sign Up
Bayer Hlthcare CIPRO ciprofloxacin FOR SUSPENSION;ORAL 020780-001 Sep 26, 1997 ⤷  Sign Up ⤷  Sign Up
Bayer Pharms CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER ciprofloxacin INJECTABLE;INJECTION 019858-001 Dec 26, 1990 ⤷  Sign Up ⤷  Sign Up
Bayer Hlthcare CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER ciprofloxacin INJECTABLE;INJECTION 019857-001 Dec 26, 1990 ⤷  Sign Up ⤷  Sign Up
Bayer Hlthcare CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER ciprofloxacin INJECTABLE;INJECTION 019857-001 Dec 26, 1990 ⤷  Sign Up ⤷  Sign Up
Bayer Hlthcare CIPRO ciprofloxacin INJECTABLE;INJECTION 019847-001 Dec 26, 1990 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for CIPROFLOXACIN

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 2010074992 ⤷  Sign Up
South Korea 20100135299 AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS ⤷  Sign Up
Russian Federation 2011105257 МОДУЛИРУЮЩИЕ АПОПТОЗ КОМПОЗИЦИИ С КОНТРОЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ И СПОСОБЫ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ УХА ⤷  Sign Up
South Korea 20130100017 CONTROLLED RELEASE CORTICOSTEROID COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS ⤷  Sign Up
World Intellectual Property Organization (WIPO) 2016004231 ⤷  Sign Up
Australia 2009274137 Controlled release antimicrobial compositions and methods for the treatment of otic disorders ⤷  Sign Up
Australia 2009274229 Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for CIPROFLOXACIN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1429780 SPC/GB12/058 United Kingdom ⤷  Sign Up PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
1429780 122012000070 Germany ⤷  Sign Up PRODUCT NAME: KOMBINATION AUS CIPROFLOXACIN UND DEXAMETHASON, INSBESONDERE CIPROFLOXACINHYDROCHLORID UND DEXAMETHASON; NAT. REGISTRATION NO/DATE: 85150.00. 00 20120830; FIRST REGISTRATION: DAENEMARK 48976 20120808
1429780 13C0012 France ⤷  Sign Up PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808
1429780 132013902137451 Italy ⤷  Sign Up PRODUCT NAME: CIPROFLOXACINA E DESAMETASONE(CILODEX); AUTHORISATION NUMBER(S) AND DATE(S): 48976, 20120810;041182015/M, 20121106
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.